Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nuvo Research Earns Galderma Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Nuvo Research Earns Galderma Milestone

EU marketing licenses trigger $6 million payment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galderma has received its first three Pliaglis marketing licenses from E.U. countries, triggering a $6 million milestone payment to partner Nuvo Research. The milestone payments are due on the launch of Pliaglis in the approved countries or six months from the date of marketing approval. The payments are expected in December 2012 ($5.0 million) and January 2013 ($1.0 million). Galderma plans to launch Pliaglis in the E.U. and other territories in 1H13.
 
“We are extremely pleased that Pliaglis is in the process of being approved in a number of E.U. countries and that Nuvo is receiving a substantial regulatory milestone payment as a result,” said Dr. Bradley Galer, president of Nuvo’s Pain Group. “The upcoming launch of Pliaglis will mean that Nuvo will have 3 growing sources of revenue from globally commercialized topical pain products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics